Skip to content

A Study in Participants With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor

A Randomized Placebo-Controlled, Double-Blind Study of LY2216684 Flexible-Dose 12 to 18 mg Once Daily as Adjunctive Treatment for Patients With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor Treatment

Status
Completed
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01185340
Enrollment
1056
Registered
2010-08-19
Start date
2011-03-31
Completion date
2013-04-30
Last updated
2018-04-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Major Depressive Disorder

Keywords

Depression, MDD

Brief summary

The primary objective of this study is to assess whether LY2216684 12 milligrams (mg) or 18 mg flexible dose once daily is superior to placebo once daily in the adjunctive treatment of participants with major depressive disorder (MDD) who are partial responders to their selective serotonin reuptake inhibitor (SSRI) treatment.

Detailed description

Following the Confirmation (CF) Phase, participants were randomized to adjunctive LY2216684 or adjunctive placebo if they had \<25% improvement in the Montgomery-Åsberg Depression Rating Scale (MADRS) total score over the past 3 weeks and a current MADRS total score ≥14. Participants who did not meet criteria received adjunctive placebo to preserve the blind.

Interventions

DRUGLY2216684
DRUGPlacebo
DRUGSSRI

Participants should have been on their SSRI for at least 6 weeks prior and were to continue on their stable dose throughout the study

Sponsors

Eli Lilly and Company
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Women of child-bearing potential may participate but must test negative for pregnancy at the time of study entry; both women/men agree to use a reliable method of birth control * Are being treated with one of the following selective serotonin reuptake inhibitors (SSRIs): escitalopram, citalopram, sertraline, fluoxetine, paroxetine, or fluvoxamine; for at least 6 weeks prior to investigational product dispensing with at least the last 4 weeks at a stable, optimized dose * Drug and dosage should be within the labeling guidelines for the specific country * Meet criteria for major depressive disorder (MDD), as defined by Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision® (DSM-IV-TR) criteria * Meet criteria for partial response, as defined by investigator's opinion that the participant has experienced a minimal clinically meaningful improvement with SSRI * Have a GRID 17-Item Hamilton Depression Rating Scale (GRID-HAMD17) total score greater than or equal to 16 at screening * Have less than or equal to 75% improvement on the current SSRI at screening determined by the Massachusetts General Hospital Antidepressant Treatment Response Questionnaire (MGH-ATRQ)

Exclusion criteria

* Have had or currently have any additional ongoing DSM-IV-TR Axis 1 condition other than major depression within 1 year of screening * Have had any anxiety disorder that was considered a primary diagnosis within the past year (including panic disorder, obsessive-compulsive disorder \[OCD\], post-traumatic stress disorder \[PTSD\], generalized anxiety disorder \[GAD\], and social phobia, but excluding specific phobias) * Have a current or previous diagnosis of a bipolar disorder, schizophrenia, or other psychotic disorder * Have a history of substance abuse and/or dependence within the past year (drug categories defined by DSM-IV-TR), not including caffeine and nicotine * Have an Axis II disorder that, in the judgment of the investigator, would interfere with compliance with protocol * Unstable medical conditions that contraindicate the use of LY2216684 * Have any diagnosed medical condition that could be exacerbated by noradrenergic agents, including unstable hypertension, unstable heart disease, tachycardia, tachyarrhythmia, narrow-angled glaucoma, history of urinary hesitancy or retention * Use of excluded concomitant or psychotropic medication other than SSRI * Have initiated or discontinued hormone therapy within the 3 months prior to enrollment * History of treatment-resistant depression as shown by lack of response of the current depressive episode to 2 or more adequate courses of antidepressant therapy at a clinically appropriate dose for at least 4 weeks or, in the judgment of the investigator, the participant has treatment-resistant depression * Have a lifetime history of vagal nerve stimulation (VNS), transcranial magnetic stimulation (TMS), or psychosurgery * Have received electroconvulsive therapy (ECT) in the past year

Design outcomes

Primary

MeasureTime frameDescription
Change From Randomization to Week 8 in Montgomery-Asberg Depression Rating Scale (MADRS) Total ScoreRandomization, 8 weeksThe Montgomery-Asberg Depression Rating Scale (MADRS) is a rating scale for severity of depressive mood symptoms. The MADRS had a 10-item checklist. Items were rated on a scale of 0 to 6, for a total score range of 0 (low severity of depressive symptoms) to 60 (high severity of depressive symptoms). Least Squares (LS) means were calculated using mixed model repeated measures (MMRM) adjusting for treatment, investigator, visit, baseline score, treatment-by-visit, and baseline score-by-visit.

Secondary

MeasureTime frameDescription
Change From Randomization to Week 8 in Fatigue Associated With Depression (FAsD) Impact Subscale ScoreRandomization, 8 weeksThe Fatigue Associated with Depression (FAsD) is a participant-rated scale with a total of 13 items. Six of the 13 items ask how often participants experience different aspects of fatigue with responses from 1 (never) to 5 (always). Seven of the 13 items ask how often fatigue impacts various aspects of the participant's lives with responses from 1 (not at all) to 5 (very much). The impact subscale score was derived by taking the mean of Items 7 through 13 (applicable items only). Item 12 applied only to participants with a spouse or significant other, and Item 13 applied to participants who had a job or who went to school. The FAsD impact subscale score ranges from 1 to 5. Least Squares (LS) means were calculated using mixed model repeated measures (MMRM) adjusting for treatment, investigator, visit, baseline subscale score, treatment-by-visit, and baseline subscale score-by-visit.
Probability of Participants Achieving a Montgomery-Asberg Depression Rating Scale (MADRS) Total Score of Less Than or Equal to 10 at Week 88 weeksA Montgomery-Asberg Depression Rating Scale (MADRS) total score of less than or equal to 10 was defined as remission criteria. The MADRS is a rating scale for severity of depressive mood symptoms. The MADRS had a 10-item checklist. Items were rated on a scale of 0 to 6, for a total score range of 0 (low severity of depressive symptoms) to 60 (high severity of depressive symptoms). A categorical repeated measures analysis modeled the probability of remission at each visit, and the estimated probabilities were adjusted for treatment, visit, baseline MADRS total score, and treatment-by-visit.
Percentage of Participants Achieving a Montgomery-Asberg Depression Rating Scale (MADRS) Total Score of Less Than or Equal to 10 for at Least 2 Consecutive Measurements, Including the Participant's Last MeasurementRandomization up to 8 weeksA Montgomery-Asberg Depression Rating Scale (MADRS) total score of less than or equal to 10 for at least 2 consecutive measurements, including the participant's last measurement was defined as remission criteria at last 2 consecutive visits. The MADRS is a rating scale for severity of depressive mood symptoms. The MADRS had a 10-item checklist. Items were rated on a scale of 0 to 6, for a total score range of 0 (low severity of depressive symptoms) to 60 (high severity of depressive symptoms). Percentage of participants was calculated by dividing the number of participants who meet criteria for remission at last 2 consecutive visits by the total number of participants analyzed, multiplied by 100%.
Change From Randomization to Week 8 in Hospital and Anxiety and Depression Scale (HADS) Anxiety Subscale ScoreRandomization, 8 weeksThe Hospital Anxiety and Depression Scale (HADS) is a 14-item questionnaire with 2 subscales: anxiety and depression. Each item was rated on a 4-point scale (0-3), giving maximum scores of 21 for anxiety and depression subscale. Scores of 11 or more on either subscale were considered to be a significant 'case' of psychological morbidity, while scores of 8-10 represent 'borderline' and 0-7 represent 'normal'. Least Squares (LS) means were calculated using mixed model repeated measures (MMRM) adjusting for treatment, investigator, visit, baseline subscale score, treatment-by-visit, and baseline subscale score-by-visit.
Probability of Participants Who Have a Greater Than or Equal to 50 Percent Improvement in the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score at Week 88 weeksA greater than or equal to 50 percent improvement (that is, a decrease from baseline) in the Montgomery-Asberg Depression Rating Scale (MADRS) total score was defined as response criteria. The MADRS is a rating scale for severity of depressive mood symptoms. The MADRS had a 10-item checklist. Items were rated on a scale of 0 to 6, for a total score range of 0 (low severity of depressive symptoms) to 60 (high severity of depressive symptoms). A categorical repeated measures analysis modeled the probability of response at each visit, and the estimated probabilities were adjusted for treatment, visit, baseline MADRS total score, and treatment-by-visit.
Change From Randomization to Week 8 in The Hospital Anxiety and Depression Scale (HADS) Depression Subscale ScoreRandomization, 8 weeksThe Hospital Anxiety and Depression Scale (HADS) is a 14-item questionnaire with 2 subscales: anxiety and depression. Each item was rated on a 4-point scale (0-3), giving maximum scores of 21 for anxiety and depression subscale. Scores of 11 or more on either subscale were considered to be a significant 'case' of psychological morbidity, while scores of 8-10 represent 'borderline' and 0-7 represent 'normal'. Least Squares (LS) means were calculated using mixed model repeated measures (MMRM) adjusting for treatment, investigator, visit, baseline subscale score, treatment-by-visit, and baseline subscale score-by-visit.
Change From Randomization to Week 8 in Montgomery-Asberg Depression Rating Scale (MADRS) Individual ItemsRandomization, 8 weeksThe Montgomery-Asberg Depression Rating Scale (MADRS) is a rating scale for severity of depressive mood symptoms. The MADRS had a 10-item checklist. Items were rated on a scale of 0 to 6, for a total score range of 0 (low severity of depressive symptoms) to 60 (high severity of depressive symptoms). Least Squares (LS) means were calculated using mixed model repeated measures (MMRM) adjusting for treatment, investigator, visit, baseline item score, treatment-by-visit and baseline item score-by-visit.
Change From Randomization to Week 8 in Clinical Global Impressions of Severity (CGI-S)Randomization, 8 weeksClinical Global Impression - Severity (CGI-S) measures severity of depression at the time of assessment compared with the start of treatment. Scores range from 1 (normal, not at all ill) to 7 (among the most extremely ill participants). Least Squares (LS) means were calculated using mixed model repeated measures (MMRM) adjusting for treatment, investigator, visit, baseline score, treatment-by-visit, and baseline score-by-visit.
Change From Randomization to Week 8 in Sheehan Disability Scale (SDS) Global Functional Impairment ScoreRandomization, 8 weeksThe Sheehan Disability Scale (SDS) was completed by the participant and used to assess the effect of the participant's symptoms on their work (Item 1), social (Item 2), and family life (Item 3). Each item is measured on a 0 (not at all) to 10 (extremely) point scale with higher values indicating greater disruption. The Global Functional Impairment Score is the sum of the 3 items, and scores ranged from 0 to 30 with higher values indicating greater disruption in the participant's work life (work/school impairment score), social life (social life/leisure activities impairment score), and family life (family life/home responsibilities impairment score). Least Squares (LS) means were calculated using mixed model repeated measures (MMRM) adjusting for treatment, investigator, visit, baseline score, treatment-by-visit, and baseline score-by-visit.
Change From Randomization to Week 8 in Sheehan Disability Scale (SDS) ItemsRandomization, 8 weeksThe Sheehan Disability Scale (SDS) was completed by the participant and used to assess the effect of the participant's symptoms on their work (work/school impairment score), social life (social life/leisure activities impairment score), and family life (family life/home responsibilities impairment score). Each item is measured on a 0 (not at all) to 10 (extremely) point scale with higher values indicating greater disruption. Least Squares (LS) means were calculated using mixed model repeated measures (MMRM) adjusting for treatment, investigator, visit, baseline item score, treatment-by-visit, and baseline item score-by-visit.
Change From Randomization to Week 8 in the Quality of Life Enjoyment and Satisfaction Questionnaire-Short Form (Q-LES-Q-SF)Randomization, 8 weeksThe Quality of Life Enjoyment and Satisfaction Questionnaire-Short Form (Q-LES-Q-SF) is a self-administered, 16-item questionnaire measuring degree of enjoyment and satisfaction experienced in various areas of daily life during the past week on a 5-point Likert scale (1=very poor and 5=very good). The total raw score is the sum of Items 1 to 14 and ranges from 14 to 70. The raw scores are converted to and expressed as the percentage of the maximum possible score. Higher scores indicate higher levels of enjoyment/satisfaction. Least Squares (LS) means were calculated using mixed model repeated measures (MMRM) adjusting for treatment, investigator, visit, baseline score, treatment-by-visit, and baseline score-by-visit.
Change From Randomization to Week 8 in the EuroQol Questionnaire-5 Dimension (EQ-5D)Randomization, 8 weeksThe EQ-5D Visual Analog Scale is a generic, multidimensional, health-related, quality-of-life instrument. Overall health state score is self-reported using a visual analogue scale, marked on a scale of 0 to 100 with 0 representing worst imaginable health state and 100 representing best imaginable health state. Least Squares (LS) means were calculated using mixed model repeated measures (MMRM) adjusting for treatment, investigator, visit, baseline score, treatment-by-visit, and baseline score-by-visit.
Percentage of Participants With Treatment-emergent Suicidal Ideation and Behaviors Assessed by Columbia-Suicide Severity Rating Scale (C-SSRS)Randomization up to 8 weeksThe Columbia-Suicide Severity Rating Scale (C-SSRS) captured occurrence, severity, and frequency of suicide-related thoughts and behaviors. Suicidal ideation was defined as a yes answer to any 1 of 5 suicidal ideation questions, which included a wish to be dead and 4 different categories of active suicidal ideation. Suicidal behavior was defined as a yes answer to any of 5 suicidal behavior questions: preparatory acts or behavior, aborted attempt, interrupted attempt, actual attempt, and completed suicide. Suicidal ideation and behavior are defined as treatment-emergent (TE) if not present at baseline. Percentage of participants was calculated by dividing the number of participants with suicide-related TE events by the total number of participants at risk, multiplied by 100%. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Event module.
Change From Randomization to Week 8 in Arizona Sexual Experiences (ASEX) ScaleRandomization, 8 weeksThe Arizona Sexual Experiences (ASEX) scale was used to assess sexual functioning in both males and females. The ASEX total score for the male and female version was calculated as the sum of the responses (rated from 1 \[extremely\] to 6 \[no/never\]) of the 5 items of the ASEX scale. Total scores ranged from 5 to 30, with higher scores indicating greater sexual dysfunction. Least Squares (LS) means were calculated using mixed model repeated measures (MMRM) adjusting for treatment, investigator, visit, baseline score, treatment-by-visit, and baseline score-by-visit.
Change From Randomization to Week 8 in Massachusetts General Hospital Cognitive and Physical Functioning Questionnaire (CPFQ)Randomization, 8 weeksThe Massachusetts General Hospital Cognitive and Physical Functioning Questionnaire (CPFQ) is a 7-item participant-rated questionnaire pertaining to a participant's cognitive and physical well-being. It assesses motivation, wakefulness, energy, focus, recall, word-finding difficulty, and mental acuity. Each item was scored on a 6-point scale ranging from 1 (greater than normal) to 6 (totally absent). Total scores ranged from 7 to 42. Higher scores indicate greater disease severity. Least Squares (LS) means were calculated using mixed model repeated measures (MMRM) adjusting for treatment, investigator, visit, baseline score, treatment-by-visit, and baseline score-by-visit.
Change From Randomization to Week 8 in Blood PressureRandomization, 8 weeksBlood pressure measurements were collected when the participant was in a sitting position. Three measurements of sitting blood pressure collected at approximately 1-minute intervals at every visit were averaged and used as the value for the visit. Least Squares (LS) means were calculated using mixed model repeated measures (MMRM) adjusting for treatment, investigator, visit, baseline value, treatment-by-visit, and baseline value-by-visit.
Change From Randomization to Week 8 in Pulse RateRandomization, 8 weeksPulse measurements were collected when the participant was in a sitting position. Least Squares (LS) means were calculated using mixed model repeated measures (MMRM) adjusting for treatment, investigator, visit, baseline value, treatment-by-visit, and baseline value-by-visit.
Change From Randomization to Week 8 in Fatigue Associated With Depression (FAsD) Average Score and Experience Subscale ScoreRandomization, 8 weeksThe Fatigue Associated with Depression (FAsD) is a participant-rated scale with a total of 13 items. Six of the 13 items ask how often participants experience different aspects of fatigue with responses from 1 (never) to 5 (always). Seven of the 13 items ask how often fatigue impacts various aspects of the participant's lives with responses from 1 (not at all) to 5 (very much). The experience subscale score was derived by taking the mean of Items 1 through 6, and the average score was the mean of Items 1 through 13 (derived by taking the mean of all applicable items for each participant). Item 12 applied only to participants with a spouse or significant other, and Item 13 applied to participants who had a job or who went to school. Least Squares (LS) means were calculated using mixed model repeated measures (MMRM) adjusting for treatment, investigator, visit, baseline score, treatment-by-visit, and baseline score-by-visit.

Countries

Australia, Austria, Belgium, Germany, Sweden, United Kingdom, United States

Participant flow

Pre-assignment details

The first 3 weeks of the study was a double-blind Confirmation Phase during which participants continued to receive their SSRI with adjunctive placebo. If randomization criteria were met, participants were randomized to adjunctive LY2216684 or adjunctive placebo. If criteria were not met, participants continued on placebo to maintain the blind.

Participants by arm

ArmCount
LY2216684 + SSRI (Randomized Participants)
LY2216684: 12 or 18 milligrams (mg), administered orally, once daily for 8 weeks, adjunctive to a selective serotonin reuptake inhibitor (SSRI)
230
Placebo + SSRI (Randomized Participants)
Placebo: Administered orally, once daily for 8 weeks, adjunctive to a selective serotonin reuptake inhibitor (SSRI)
219
Placebo + SSRI (Non-randomized Participants)
Placebo: Administered orally, once daily for 8 weeks, adjunctive to a selective serotonin reuptake inhibitor (SSRI)
519
Total968

Withdrawals & dropouts

PeriodReasonFG000FG001FG002FG003
Adjunctive Treatment (AT) Phase, 8 WeeksAdverse Event013813
Adjunctive Treatment (AT) Phase, 8 WeeksLack of Efficacy0474
Adjunctive Treatment (AT) Phase, 8 WeeksLost to Follow-up0457
Adjunctive Treatment (AT) Phase, 8 WeeksPhysician Decision0101
Adjunctive Treatment (AT) Phase, 8 WeeksProtocol Violation0525
Adjunctive Treatment (AT) Phase, 8 WeeksSponsor Decision0037
Adjunctive Treatment (AT) Phase, 8 WeeksWithdrawal by Subject08824
Confirmation (CF) Phase, 3 WeeksAdverse Event24000
Confirmation (CF) Phase, 3 WeeksLack of Efficacy6000
Confirmation (CF) Phase, 3 WeeksLost to Follow-up5000
Confirmation (CF) Phase, 3 WeeksPhysician Decision2000
Confirmation (CF) Phase, 3 WeeksProtocol Violation16000
Confirmation (CF) Phase, 3 WeeksSponsor Decision3000
Confirmation (CF) Phase, 3 WeeksWithdrawal by Subject32000

Baseline characteristics

CharacteristicPlacebo + SSRI (Non-randomized Participants)Placebo + SSRI (Randomized Participants)LY2216684 + SSRI (Randomized Participants)Total
Age, Continuous47.39 years
STANDARD_DEVIATION 12.68
48.44 years
STANDARD_DEVIATION 11.39
48.29 years
STANDARD_DEVIATION 11.9
47.84 years
STANDARD_DEVIATION 12.21
Ethnicity (NIH/OMB)
Hispanic or Latino
31 Participants12 Participants19 Participants62 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
370 Participants158 Participants164 Participants692 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
118 Participants49 Participants47 Participants214 Participants
Race (NIH/OMB)
American Indian or Alaska Native
3 Participants0 Participants0 Participants3 Participants
Race (NIH/OMB)
Asian
3 Participants1 Participants2 Participants6 Participants
Race (NIH/OMB)
Black or African American
53 Participants31 Participants17 Participants101 Participants
Race (NIH/OMB)
More than one race
2 Participants2 Participants4 Participants8 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants0 Participants0 Participants0 Participants
Race (NIH/OMB)
Unknown or Not Reported
1 Participants0 Participants0 Participants1 Participants
Race (NIH/OMB)
White
457 Participants185 Participants207 Participants849 Participants
Region of Enrollment
Australia
84 Participants20 Participants22 Participants126 Participants
Region of Enrollment
Austria
25 Participants10 Participants10 Participants45 Participants
Region of Enrollment
Belgium
13 Participants4 Participants7 Participants24 Participants
Region of Enrollment
Germany
95 Participants63 Participants58 Participants216 Participants
Region of Enrollment
Sweden
77 Participants18 Participants21 Participants116 Participants
Region of Enrollment
United Kingdom
30 Participants15 Participants19 Participants64 Participants
Region of Enrollment
United States
195 Participants89 Participants93 Participants377 Participants
Sex: Female, Male
Female
354 Participants145 Participants155 Participants654 Participants
Sex: Female, Male
Male
165 Participants74 Participants75 Participants314 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
EG002
affected / at risk
EG003
affected / at risk
EG004
affected / at risk
EG005
affected / at risk
EG006
affected / at risk
EG007
affected / at risk
deaths
Total, all-cause mortality
— / —— / —— / —— / —— / —— / —— / —— / —
other
Total, other adverse events
270 / 1,05287 / 22844 / 218128 / 5195 / 1839 / 20622 / 20270 / 482
serious
Total, serious adverse events
9 / 1,0527 / 2287 / 21812 / 5191 / 182 / 2064 / 2024 / 482

Outcome results

Primary

Change From Randomization to Week 8 in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score

The Montgomery-Asberg Depression Rating Scale (MADRS) is a rating scale for severity of depressive mood symptoms. The MADRS had a 10-item checklist. Items were rated on a scale of 0 to 6, for a total score range of 0 (low severity of depressive symptoms) to 60 (high severity of depressive symptoms). Least Squares (LS) means were calculated using mixed model repeated measures (MMRM) adjusting for treatment, investigator, visit, baseline score, treatment-by-visit, and baseline score-by-visit.

Time frame: Randomization, 8 weeks

Population: All randomized participants who have non-missing values at the time of randomization and at least one post-randomization value.

ArmMeasureValue (LEAST_SQUARES_MEAN)Dispersion
LY2216684 + SSRIChange From Randomization to Week 8 in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score-8.73 units on a scaleStandard Error 0.55
Placebo + SSRIChange From Randomization to Week 8 in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score-8.49 units on a scaleStandard Error 0.57
p-value: 0.751Mixed Models Analysis
Secondary

Change From Randomization to Week 8 in Arizona Sexual Experiences (ASEX) Scale

The Arizona Sexual Experiences (ASEX) scale was used to assess sexual functioning in both males and females. The ASEX total score for the male and female version was calculated as the sum of the responses (rated from 1 \[extremely\] to 6 \[no/never\]) of the 5 items of the ASEX scale. Total scores ranged from 5 to 30, with higher scores indicating greater sexual dysfunction. Least Squares (LS) means were calculated using mixed model repeated measures (MMRM) adjusting for treatment, investigator, visit, baseline score, treatment-by-visit, and baseline score-by-visit.

Time frame: Randomization, 8 weeks

Population: All randomized participants who have non-missing values at the time of randomization and at least one post-randomization value.

ArmMeasureValue (LEAST_SQUARES_MEAN)Dispersion
LY2216684 + SSRIChange From Randomization to Week 8 in Arizona Sexual Experiences (ASEX) Scale-0.92 units on a scaleStandard Error 0.25
Placebo + SSRIChange From Randomization to Week 8 in Arizona Sexual Experiences (ASEX) Scale-0.68 units on a scaleStandard Error 0.26
Secondary

Change From Randomization to Week 8 in Blood Pressure

Blood pressure measurements were collected when the participant was in a sitting position. Three measurements of sitting blood pressure collected at approximately 1-minute intervals at every visit were averaged and used as the value for the visit. Least Squares (LS) means were calculated using mixed model repeated measures (MMRM) adjusting for treatment, investigator, visit, baseline value, treatment-by-visit, and baseline value-by-visit.

Time frame: Randomization, 8 weeks

Population: All randomized participants who have non-missing values at the time of randomization and at least one post-randomization value.

ArmMeasureGroupValue (LEAST_SQUARES_MEAN)Dispersion
LY2216684 + SSRIChange From Randomization to Week 8 in Blood PressureSystolic blood pressure3.09 millimeters of mercury (mmHg)Standard Error 0.67
LY2216684 + SSRIChange From Randomization to Week 8 in Blood PressureDiastolic blood pressure4.54 millimeters of mercury (mmHg)Standard Error 0.53
Placebo + SSRIChange From Randomization to Week 8 in Blood PressureSystolic blood pressure0.27 millimeters of mercury (mmHg)Standard Error 0.69
Placebo + SSRIChange From Randomization to Week 8 in Blood PressureDiastolic blood pressure0.53 millimeters of mercury (mmHg)Standard Error 0.54
Secondary

Change From Randomization to Week 8 in Clinical Global Impressions of Severity (CGI-S)

Clinical Global Impression - Severity (CGI-S) measures severity of depression at the time of assessment compared with the start of treatment. Scores range from 1 (normal, not at all ill) to 7 (among the most extremely ill participants). Least Squares (LS) means were calculated using mixed model repeated measures (MMRM) adjusting for treatment, investigator, visit, baseline score, treatment-by-visit, and baseline score-by-visit.

Time frame: Randomization, 8 weeks

Population: All randomized participants who have non-missing values at the time of randomization and at least one post-randomization value.

ArmMeasureValue (LEAST_SQUARES_MEAN)Dispersion
LY2216684 + SSRIChange From Randomization to Week 8 in Clinical Global Impressions of Severity (CGI-S)-1.08 units on a scaleStandard Error 0.08
Placebo + SSRIChange From Randomization to Week 8 in Clinical Global Impressions of Severity (CGI-S)-1.02 units on a scaleStandard Error 0.08
Secondary

Change From Randomization to Week 8 in Fatigue Associated With Depression (FAsD) Average Score and Experience Subscale Score

The Fatigue Associated with Depression (FAsD) is a participant-rated scale with a total of 13 items. Six of the 13 items ask how often participants experience different aspects of fatigue with responses from 1 (never) to 5 (always). Seven of the 13 items ask how often fatigue impacts various aspects of the participant's lives with responses from 1 (not at all) to 5 (very much). The experience subscale score was derived by taking the mean of Items 1 through 6, and the average score was the mean of Items 1 through 13 (derived by taking the mean of all applicable items for each participant). Item 12 applied only to participants with a spouse or significant other, and Item 13 applied to participants who had a job or who went to school. Least Squares (LS) means were calculated using mixed model repeated measures (MMRM) adjusting for treatment, investigator, visit, baseline score, treatment-by-visit, and baseline score-by-visit.

Time frame: Randomization, 8 weeks

Population: All randomized participants who have non-missing values at the time of randomization and at least one post-randomization value.

ArmMeasureGroupValue (LEAST_SQUARES_MEAN)Dispersion
LY2216684 + SSRIChange From Randomization to Week 8 in Fatigue Associated With Depression (FAsD) Average Score and Experience Subscale ScoreFAsD average score-0.62 units on a scaleStandard Error 0.06
LY2216684 + SSRIChange From Randomization to Week 8 in Fatigue Associated With Depression (FAsD) Average Score and Experience Subscale ScoreFAsD experience subscale score-0.57 units on a scaleStandard Error 0.06
Placebo + SSRIChange From Randomization to Week 8 in Fatigue Associated With Depression (FAsD) Average Score and Experience Subscale ScoreFAsD average score-0.55 units on a scaleStandard Error 0.06
Placebo + SSRIChange From Randomization to Week 8 in Fatigue Associated With Depression (FAsD) Average Score and Experience Subscale ScoreFAsD experience subscale score-0.50 units on a scaleStandard Error 0.06
Secondary

Change From Randomization to Week 8 in Fatigue Associated With Depression (FAsD) Impact Subscale Score

The Fatigue Associated with Depression (FAsD) is a participant-rated scale with a total of 13 items. Six of the 13 items ask how often participants experience different aspects of fatigue with responses from 1 (never) to 5 (always). Seven of the 13 items ask how often fatigue impacts various aspects of the participant's lives with responses from 1 (not at all) to 5 (very much). The impact subscale score was derived by taking the mean of Items 7 through 13 (applicable items only). Item 12 applied only to participants with a spouse or significant other, and Item 13 applied to participants who had a job or who went to school. The FAsD impact subscale score ranges from 1 to 5. Least Squares (LS) means were calculated using mixed model repeated measures (MMRM) adjusting for treatment, investigator, visit, baseline subscale score, treatment-by-visit, and baseline subscale score-by-visit.

Time frame: Randomization, 8 weeks

Population: All randomized participants who have non-missing values at the time of randomization and at least one post-randomization value.

ArmMeasureValue (LEAST_SQUARES_MEAN)Dispersion
LY2216684 + SSRIChange From Randomization to Week 8 in Fatigue Associated With Depression (FAsD) Impact Subscale Score-0.69 units on a scaleStandard Error 0.06
Placebo + SSRIChange From Randomization to Week 8 in Fatigue Associated With Depression (FAsD) Impact Subscale Score-0.59 units on a scaleStandard Error 0.07
Secondary

Change From Randomization to Week 8 in Hospital and Anxiety and Depression Scale (HADS) Anxiety Subscale Score

The Hospital Anxiety and Depression Scale (HADS) is a 14-item questionnaire with 2 subscales: anxiety and depression. Each item was rated on a 4-point scale (0-3), giving maximum scores of 21 for anxiety and depression subscale. Scores of 11 or more on either subscale were considered to be a significant 'case' of psychological morbidity, while scores of 8-10 represent 'borderline' and 0-7 represent 'normal'. Least Squares (LS) means were calculated using mixed model repeated measures (MMRM) adjusting for treatment, investigator, visit, baseline subscale score, treatment-by-visit, and baseline subscale score-by-visit.

Time frame: Randomization, 8 weeks

Population: All randomized participants who have non-missing values at the time of randomization and at least one post-randomization value.

ArmMeasureValue (LEAST_SQUARES_MEAN)Dispersion
LY2216684 + SSRIChange From Randomization to Week 8 in Hospital and Anxiety and Depression Scale (HADS) Anxiety Subscale Score-2.20 units on a scaleStandard Error 0.22
Placebo + SSRIChange From Randomization to Week 8 in Hospital and Anxiety and Depression Scale (HADS) Anxiety Subscale Score-1.78 units on a scaleStandard Error 0.23
Secondary

Change From Randomization to Week 8 in Massachusetts General Hospital Cognitive and Physical Functioning Questionnaire (CPFQ)

The Massachusetts General Hospital Cognitive and Physical Functioning Questionnaire (CPFQ) is a 7-item participant-rated questionnaire pertaining to a participant's cognitive and physical well-being. It assesses motivation, wakefulness, energy, focus, recall, word-finding difficulty, and mental acuity. Each item was scored on a 6-point scale ranging from 1 (greater than normal) to 6 (totally absent). Total scores ranged from 7 to 42. Higher scores indicate greater disease severity. Least Squares (LS) means were calculated using mixed model repeated measures (MMRM) adjusting for treatment, investigator, visit, baseline score, treatment-by-visit, and baseline score-by-visit.

Time frame: Randomization, 8 weeks

Population: All randomized participants who have non-missing values at the time of randomization and at least one post-randomization value.

ArmMeasureValue (LEAST_SQUARES_MEAN)Dispersion
LY2216684 + SSRIChange From Randomization to Week 8 in Massachusetts General Hospital Cognitive and Physical Functioning Questionnaire (CPFQ)-4.12 units on a scaleStandard Error 0.39
Placebo + SSRIChange From Randomization to Week 8 in Massachusetts General Hospital Cognitive and Physical Functioning Questionnaire (CPFQ)-3.68 units on a scaleStandard Error 0.4
Secondary

Change From Randomization to Week 8 in Montgomery-Asberg Depression Rating Scale (MADRS) Individual Items

The Montgomery-Asberg Depression Rating Scale (MADRS) is a rating scale for severity of depressive mood symptoms. The MADRS had a 10-item checklist. Items were rated on a scale of 0 to 6, for a total score range of 0 (low severity of depressive symptoms) to 60 (high severity of depressive symptoms). Least Squares (LS) means were calculated using mixed model repeated measures (MMRM) adjusting for treatment, investigator, visit, baseline item score, treatment-by-visit and baseline item score-by-visit.

Time frame: Randomization, 8 weeks

Population: All randomized participants who have non-missing values at the time of randomization and at least one post-randomization value.

ArmMeasureGroupValue (LEAST_SQUARES_MEAN)Dispersion
LY2216684 + SSRIChange From Randomization to Week 8 in Montgomery-Asberg Depression Rating Scale (MADRS) Individual ItemsApparent Sadness-1.10 units on a scaleStandard Error 0.09
LY2216684 + SSRIChange From Randomization to Week 8 in Montgomery-Asberg Depression Rating Scale (MADRS) Individual ItemsReported Sadness-1.17 units on a scaleStandard Error 0.09
LY2216684 + SSRIChange From Randomization to Week 8 in Montgomery-Asberg Depression Rating Scale (MADRS) Individual ItemsInner Tension-0.72 units on a scaleStandard Error 0.08
LY2216684 + SSRIChange From Randomization to Week 8 in Montgomery-Asberg Depression Rating Scale (MADRS) Individual ItemsReduced Sleep-0.83 units on a scaleStandard Error 0.09
LY2216684 + SSRIChange From Randomization to Week 8 in Montgomery-Asberg Depression Rating Scale (MADRS) Individual ItemsReduced Appetite-0.54 units on a scaleStandard Error 0.08
LY2216684 + SSRIChange From Randomization to Week 8 in Montgomery-Asberg Depression Rating Scale (MADRS) Individual ItemsConcentration Difficulties-1.07 units on a scaleStandard Error 0.09
LY2216684 + SSRIChange From Randomization to Week 8 in Montgomery-Asberg Depression Rating Scale (MADRS) Individual ItemsLassitude-1.11 units on a scaleStandard Error 0.09
LY2216684 + SSRIChange From Randomization to Week 8 in Montgomery-Asberg Depression Rating Scale (MADRS) Individual ItemsInability to Feel-1.17 units on a scaleStandard Error 0.09
LY2216684 + SSRIChange From Randomization to Week 8 in Montgomery-Asberg Depression Rating Scale (MADRS) Individual ItemsPessimistic Thoughts-0.88 units on a scaleStandard Error 0.08
LY2216684 + SSRIChange From Randomization to Week 8 in Montgomery-Asberg Depression Rating Scale (MADRS) Individual ItemsSuicidal Thoughts-0.23 units on a scaleStandard Error 0.05
Placebo + SSRIChange From Randomization to Week 8 in Montgomery-Asberg Depression Rating Scale (MADRS) Individual ItemsInability to Feel-1.08 units on a scaleStandard Error 0.09
Placebo + SSRIChange From Randomization to Week 8 in Montgomery-Asberg Depression Rating Scale (MADRS) Individual ItemsApparent Sadness-1.26 units on a scaleStandard Error 0.09
Placebo + SSRIChange From Randomization to Week 8 in Montgomery-Asberg Depression Rating Scale (MADRS) Individual ItemsConcentration Difficulties-0.82 units on a scaleStandard Error 0.09
Placebo + SSRIChange From Randomization to Week 8 in Montgomery-Asberg Depression Rating Scale (MADRS) Individual ItemsReported Sadness-1.19 units on a scaleStandard Error 0.09
Placebo + SSRIChange From Randomization to Week 8 in Montgomery-Asberg Depression Rating Scale (MADRS) Individual ItemsSuicidal Thoughts-0.24 units on a scaleStandard Error 0.05
Placebo + SSRIChange From Randomization to Week 8 in Montgomery-Asberg Depression Rating Scale (MADRS) Individual ItemsInner Tension-0.71 units on a scaleStandard Error 0.09
Placebo + SSRIChange From Randomization to Week 8 in Montgomery-Asberg Depression Rating Scale (MADRS) Individual ItemsLassitude-0.98 units on a scaleStandard Error 0.09
Placebo + SSRIChange From Randomization to Week 8 in Montgomery-Asberg Depression Rating Scale (MADRS) Individual ItemsReduced Sleep-0.76 units on a scaleStandard Error 0.1
Placebo + SSRIChange From Randomization to Week 8 in Montgomery-Asberg Depression Rating Scale (MADRS) Individual ItemsPessimistic Thoughts-0.77 units on a scaleStandard Error 0.08
Placebo + SSRIChange From Randomization to Week 8 in Montgomery-Asberg Depression Rating Scale (MADRS) Individual ItemsReduced Appetite-0.72 units on a scaleStandard Error 0.08
Secondary

Change From Randomization to Week 8 in Pulse Rate

Pulse measurements were collected when the participant was in a sitting position. Least Squares (LS) means were calculated using mixed model repeated measures (MMRM) adjusting for treatment, investigator, visit, baseline value, treatment-by-visit, and baseline value-by-visit.

Time frame: Randomization, 8 weeks

Population: All randomized participants who have non-missing values at the time of randomization and at least one post-randomization value.

ArmMeasureValue (LEAST_SQUARES_MEAN)Dispersion
LY2216684 + SSRIChange From Randomization to Week 8 in Pulse Rate9.64 beats per minute (bpm)Standard Error 0.67
Placebo + SSRIChange From Randomization to Week 8 in Pulse Rate-1.49 beats per minute (bpm)Standard Error 0.69
Secondary

Change From Randomization to Week 8 in Sheehan Disability Scale (SDS) Global Functional Impairment Score

The Sheehan Disability Scale (SDS) was completed by the participant and used to assess the effect of the participant's symptoms on their work (Item 1), social (Item 2), and family life (Item 3). Each item is measured on a 0 (not at all) to 10 (extremely) point scale with higher values indicating greater disruption. The Global Functional Impairment Score is the sum of the 3 items, and scores ranged from 0 to 30 with higher values indicating greater disruption in the participant's work life (work/school impairment score), social life (social life/leisure activities impairment score), and family life (family life/home responsibilities impairment score). Least Squares (LS) means were calculated using mixed model repeated measures (MMRM) adjusting for treatment, investigator, visit, baseline score, treatment-by-visit, and baseline score-by-visit.

Time frame: Randomization, 8 weeks

Population: All randomized participants who have non-missing values at the time of randomization and at least one post-randomization value.

ArmMeasureValue (LEAST_SQUARES_MEAN)Dispersion
LY2216684 + SSRIChange From Randomization to Week 8 in Sheehan Disability Scale (SDS) Global Functional Impairment Score-4.50 units on a scaleStandard Error 0.47
Placebo + SSRIChange From Randomization to Week 8 in Sheehan Disability Scale (SDS) Global Functional Impairment Score-4.38 units on a scaleStandard Error 0.48
Secondary

Change From Randomization to Week 8 in Sheehan Disability Scale (SDS) Items

The Sheehan Disability Scale (SDS) was completed by the participant and used to assess the effect of the participant's symptoms on their work (work/school impairment score), social life (social life/leisure activities impairment score), and family life (family life/home responsibilities impairment score). Each item is measured on a 0 (not at all) to 10 (extremely) point scale with higher values indicating greater disruption. Least Squares (LS) means were calculated using mixed model repeated measures (MMRM) adjusting for treatment, investigator, visit, baseline item score, treatment-by-visit, and baseline item score-by-visit.

Time frame: Randomization, 8 weeks

Population: All randomized participants who have non-missing values at the time of randomization and at least one post-randomization value.

ArmMeasureGroupValue (LEAST_SQUARES_MEAN)Dispersion
LY2216684 + SSRIChange From Randomization to Week 8 in Sheehan Disability Scale (SDS) ItemsWork impairment score-1.41 units on a scaleStandard Error 0.22
LY2216684 + SSRIChange From Randomization to Week 8 in Sheehan Disability Scale (SDS) ItemsSocial life impairment score-1.64 units on a scaleStandard Error 0.17
LY2216684 + SSRIChange From Randomization to Week 8 in Sheehan Disability Scale (SDS) ItemsFamily life impairment score-1.56 units on a scaleStandard Error 0.17
Placebo + SSRIChange From Randomization to Week 8 in Sheehan Disability Scale (SDS) ItemsWork impairment score-1.20 units on a scaleStandard Error 0.22
Placebo + SSRIChange From Randomization to Week 8 in Sheehan Disability Scale (SDS) ItemsSocial life impairment score-1.53 units on a scaleStandard Error 0.17
Placebo + SSRIChange From Randomization to Week 8 in Sheehan Disability Scale (SDS) ItemsFamily life impairment score-1.53 units on a scaleStandard Error 0.17
Secondary

Change From Randomization to Week 8 in the EuroQol Questionnaire-5 Dimension (EQ-5D)

The EQ-5D Visual Analog Scale is a generic, multidimensional, health-related, quality-of-life instrument. Overall health state score is self-reported using a visual analogue scale, marked on a scale of 0 to 100 with 0 representing worst imaginable health state and 100 representing best imaginable health state. Least Squares (LS) means were calculated using mixed model repeated measures (MMRM) adjusting for treatment, investigator, visit, baseline score, treatment-by-visit, and baseline score-by-visit.

Time frame: Randomization, 8 weeks

Population: All randomized participants who have non-missing values at the time of randomization and at least one post-randomization value.

ArmMeasureValue (LEAST_SQUARES_MEAN)Dispersion
LY2216684 + SSRIChange From Randomization to Week 8 in the EuroQol Questionnaire-5 Dimension (EQ-5D)10.367 units on a scaleStandard Error 1.218
Placebo + SSRIChange From Randomization to Week 8 in the EuroQol Questionnaire-5 Dimension (EQ-5D)9.644 units on a scaleStandard Error 1.252
Secondary

Change From Randomization to Week 8 in The Hospital Anxiety and Depression Scale (HADS) Depression Subscale Score

The Hospital Anxiety and Depression Scale (HADS) is a 14-item questionnaire with 2 subscales: anxiety and depression. Each item was rated on a 4-point scale (0-3), giving maximum scores of 21 for anxiety and depression subscale. Scores of 11 or more on either subscale were considered to be a significant 'case' of psychological morbidity, while scores of 8-10 represent 'borderline' and 0-7 represent 'normal'. Least Squares (LS) means were calculated using mixed model repeated measures (MMRM) adjusting for treatment, investigator, visit, baseline subscale score, treatment-by-visit, and baseline subscale score-by-visit.

Time frame: Randomization, 8 weeks

Population: All randomized participants who have non-missing values at the time of randomization and at least one post-randomization value.

ArmMeasureValue (LEAST_SQUARES_MEAN)Dispersion
LY2216684 + SSRIChange From Randomization to Week 8 in The Hospital Anxiety and Depression Scale (HADS) Depression Subscale Score-2.82 units on a scaleStandard Error 0.27
Placebo + SSRIChange From Randomization to Week 8 in The Hospital Anxiety and Depression Scale (HADS) Depression Subscale Score-2.64 units on a scaleStandard Error 0.27
Secondary

Change From Randomization to Week 8 in the Quality of Life Enjoyment and Satisfaction Questionnaire-Short Form (Q-LES-Q-SF)

The Quality of Life Enjoyment and Satisfaction Questionnaire-Short Form (Q-LES-Q-SF) is a self-administered, 16-item questionnaire measuring degree of enjoyment and satisfaction experienced in various areas of daily life during the past week on a 5-point Likert scale (1=very poor and 5=very good). The total raw score is the sum of Items 1 to 14 and ranges from 14 to 70. The raw scores are converted to and expressed as the percentage of the maximum possible score. Higher scores indicate higher levels of enjoyment/satisfaction. Least Squares (LS) means were calculated using mixed model repeated measures (MMRM) adjusting for treatment, investigator, visit, baseline score, treatment-by-visit, and baseline score-by-visit.

Time frame: Randomization, 8 weeks

Population: All randomized participants who have non-missing values at the time of randomization and at least one post-randomization value.

ArmMeasureValue (LEAST_SQUARES_MEAN)Dispersion
LY2216684 + SSRIChange From Randomization to Week 8 in the Quality of Life Enjoyment and Satisfaction Questionnaire-Short Form (Q-LES-Q-SF)10.37 percentage of the maximum possible scoreStandard Error 1.09
Placebo + SSRIChange From Randomization to Week 8 in the Quality of Life Enjoyment and Satisfaction Questionnaire-Short Form (Q-LES-Q-SF)9.30 percentage of the maximum possible scoreStandard Error 1.12
Secondary

Percentage of Participants Achieving a Montgomery-Asberg Depression Rating Scale (MADRS) Total Score of Less Than or Equal to 10 for at Least 2 Consecutive Measurements, Including the Participant's Last Measurement

A Montgomery-Asberg Depression Rating Scale (MADRS) total score of less than or equal to 10 for at least 2 consecutive measurements, including the participant's last measurement was defined as remission criteria at last 2 consecutive visits. The MADRS is a rating scale for severity of depressive mood symptoms. The MADRS had a 10-item checklist. Items were rated on a scale of 0 to 6, for a total score range of 0 (low severity of depressive symptoms) to 60 (high severity of depressive symptoms). Percentage of participants was calculated by dividing the number of participants who meet criteria for remission at last 2 consecutive visits by the total number of participants analyzed, multiplied by 100%.

Time frame: Randomization up to 8 weeks

Population: All randomized participants who have non-missing values at the time of randomization and at least one post-randomization value.

ArmMeasureValue (NUMBER)
LY2216684 + SSRIPercentage of Participants Achieving a Montgomery-Asberg Depression Rating Scale (MADRS) Total Score of Less Than or Equal to 10 for at Least 2 Consecutive Measurements, Including the Participant's Last Measurement20.89 percentage of participants
Placebo + SSRIPercentage of Participants Achieving a Montgomery-Asberg Depression Rating Scale (MADRS) Total Score of Less Than or Equal to 10 for at Least 2 Consecutive Measurements, Including the Participant's Last Measurement17.89 percentage of participants
Secondary

Percentage of Participants With Treatment-emergent Suicidal Ideation and Behaviors Assessed by Columbia-Suicide Severity Rating Scale (C-SSRS)

The Columbia-Suicide Severity Rating Scale (C-SSRS) captured occurrence, severity, and frequency of suicide-related thoughts and behaviors. Suicidal ideation was defined as a yes answer to any 1 of 5 suicidal ideation questions, which included a wish to be dead and 4 different categories of active suicidal ideation. Suicidal behavior was defined as a yes answer to any of 5 suicidal behavior questions: preparatory acts or behavior, aborted attempt, interrupted attempt, actual attempt, and completed suicide. Suicidal ideation and behavior are defined as treatment-emergent (TE) if not present at baseline. Percentage of participants was calculated by dividing the number of participants with suicide-related TE events by the total number of participants at risk, multiplied by 100%. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Event module.

Time frame: Randomization up to 8 weeks

Population: All randomized participants who have non-missing values at the time of randomization and at least one post-randomization value.

ArmMeasureGroupValue (NUMBER)
LY2216684 + SSRIPercentage of Participants With Treatment-emergent Suicidal Ideation and Behaviors Assessed by Columbia-Suicide Severity Rating Scale (C-SSRS)TE suicidal ideation4.46 percentage of participants
LY2216684 + SSRIPercentage of Participants With Treatment-emergent Suicidal Ideation and Behaviors Assessed by Columbia-Suicide Severity Rating Scale (C-SSRS)TE suicidal behavior0.00 percentage of participants
Placebo + SSRIPercentage of Participants With Treatment-emergent Suicidal Ideation and Behaviors Assessed by Columbia-Suicide Severity Rating Scale (C-SSRS)TE suicidal ideation5.96 percentage of participants
Placebo + SSRIPercentage of Participants With Treatment-emergent Suicidal Ideation and Behaviors Assessed by Columbia-Suicide Severity Rating Scale (C-SSRS)TE suicidal behavior0.52 percentage of participants
Secondary

Probability of Participants Achieving a Montgomery-Asberg Depression Rating Scale (MADRS) Total Score of Less Than or Equal to 10 at Week 8

A Montgomery-Asberg Depression Rating Scale (MADRS) total score of less than or equal to 10 was defined as remission criteria. The MADRS is a rating scale for severity of depressive mood symptoms. The MADRS had a 10-item checklist. Items were rated on a scale of 0 to 6, for a total score range of 0 (low severity of depressive symptoms) to 60 (high severity of depressive symptoms). A categorical repeated measures analysis modeled the probability of remission at each visit, and the estimated probabilities were adjusted for treatment, visit, baseline MADRS total score, and treatment-by-visit.

Time frame: 8 weeks

Population: All randomized participants who have non-missing values at the time of randomization and at least one post-randomization value.

ArmMeasureValue (LEAST_SQUARES_MEAN)Dispersion
LY2216684 + SSRIProbability of Participants Achieving a Montgomery-Asberg Depression Rating Scale (MADRS) Total Score of Less Than or Equal to 10 at Week 80.313 probabilityStandard Error 0.034
Placebo + SSRIProbability of Participants Achieving a Montgomery-Asberg Depression Rating Scale (MADRS) Total Score of Less Than or Equal to 10 at Week 80.251 probabilityStandard Error 0.032
Secondary

Probability of Participants Who Have a Greater Than or Equal to 50 Percent Improvement in the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score at Week 8

A greater than or equal to 50 percent improvement (that is, a decrease from baseline) in the Montgomery-Asberg Depression Rating Scale (MADRS) total score was defined as response criteria. The MADRS is a rating scale for severity of depressive mood symptoms. The MADRS had a 10-item checklist. Items were rated on a scale of 0 to 6, for a total score range of 0 (low severity of depressive symptoms) to 60 (high severity of depressive symptoms). A categorical repeated measures analysis modeled the probability of response at each visit, and the estimated probabilities were adjusted for treatment, visit, baseline MADRS total score, and treatment-by-visit.

Time frame: 8 weeks

Population: All randomized participants who have non-missing values at the time of randomization and at least one post-randomization value.

ArmMeasureValue (LEAST_SQUARES_MEAN)Dispersion
LY2216684 + SSRIProbability of Participants Who Have a Greater Than or Equal to 50 Percent Improvement in the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score at Week 80.357 probabilityStandard Error 0.034
Placebo + SSRIProbability of Participants Who Have a Greater Than or Equal to 50 Percent Improvement in the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score at Week 80.352 probabilityStandard Error 0.034

Source: ClinicalTrials.gov · Data processed: Mar 2, 2026